Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Lymphoma Drug Development Strategies at Work - Define Your Competition

Published by: BioSeeker Group AB

Published: Jun. 22, 2009 - 535 Pages


Table of Contents


1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 Introduction

5.1 The Scope of this Report

5.2 Definitions

5.3 Abbreviations

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment

6.1.1 Carboxy-lyase Activity Targets

6.1.2 Catalytic Activity Targets

6.1.3 Cell Adhesion Molecule Activity Targets

6.1.4 Chaperone Activity Targets

6.1.5 Cysteine-Type Peptidase Activity Targets

6.1.6 Cytokine Activity Targets

6.1.7 DNA Binding Targets

6.1.8 DNA Repair Protein Targets

6.1.9 DNA Topoisomerase Activity Targets

6.1.10 DNA-Directed DNA Polymerase Activity Targets

6.1.11 Glutathione Transferase Activity Targets

6.1.12 G-Protein Coupled Receptor Activity Targets

6.1.13 Growth Factor Activity Targets

6.1.14 Hormone Activity Targets

6.1.15 Hydrolase Activity Targets

6.1.16 Kinase Activity Targets

6.1.17 Kinase Regulator Activity Targets

6.1.18 Ligand-Dependent Nuclear Receptor Activity Targets

6.1.19 Ligase Activity Targets

6.1.20 Lipid Kinase Activity Targets

6.1.21 Lipid Phosphatase Activity Targets

6.1.22 MHC Class I Receptor Activity Targets

6.1.23 Molecular Function Unknown Targets

6.1.24 Motor Activity Targets

6.1.25 Oxidoreductase Activity Targets

6.1.26 Phosphorylase Activity Targets

6.1.27 Protein Binding Targets

6.1.28 Protein Serine/Threonine Kinase Activity Targets

6.1.29 Protein Tyrosine Phosphatase Activity Targets

6.1.30 Protein-Tyrosine Kinase Activity Targets

6.1.31 Receptor Activity Targets

6.1.32 Receptor Binding Targets

6.1.33 Receptor Signaling Complex Scaffold Activity Targets

6.1.34 RNA Binding Targets

6.1.35 Serine-Type Peptidase Activity Targets

6.1.36 Structural Constituent Of Cytoskeleton Targets

6.1.37 Superoxide Dismutase Activity Targets

6.1.38 T Cell Receptor Activity Targets

6.1.39 Transcription Factor Activity Targets

6.1.40 Transcription Regulator Activity Targets

6.1.41 Translation Regulator Activity Targets

6.1.42 Transmembrane Receptor Activity Targets

6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

6.1.44 Transporter Activity Targets

6.1.45 Other Targets

6.2 The Cancer Genome Project and Lymphoma Targets

6.2.1 Lymphoma Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

6.3 Structure-based Drug Design in Lymphoma is Stimulated by Available Structure Data on Biological Targets

6.4 Target-Target Interactions among Identified Lymphoma Targets

6.5 The Drug-Target Interactome

6.6 Protein Expression Levels of Identified Drug Targets of Lymphoma Drugs

6.7 Pathway Analysis of Lymphoma Drug Targets

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline?

7.1 Terminated Drug Target Profiles in Lymphoma

7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lymphoma Pipeline

7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline

7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lymphoma Pipeline

7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline

7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lymphoma

Pipeline

7.7 Development Profiles of All Lymphoma Drug Target Profiles

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound

8.1 Small Molecules

8.1.1 Background

8.1.2 Targets in Lymphoma

8.2 Peptide/Protein Drugs

8.2.1 Background

8.2.2 Targets in Lymphoma

8.3 Antibodies and Antibody-like Structures

8.3.1 Background

8.3.2 Targets in Lymphoma

8.4 Nucleic Acid Therapies

8.4.1 Background

8.4.2 Targets in Lymphoma

8.5 Gene Therapy

8.5.1 Background

8.5.2 Targets in Lymphoma

8.6 The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma

8.7 Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets

9 Selecting a Sub-Indication of Lymphoma for Drug Development

9.1 B-cell Lymphoma

9.1.1 Players and their Compared Pipeline

9.1.2 Where is the Real Competition?

9.1.3 How Successful are They in Their Targeting Strategy?

9.2 Hodgkin’s Lymphoma

9.2.1 Players and their Compared Pipeline

9.2.2 Where is the Real Competition?

9.2.3 How Successful are They in Their Targeting Strategy?

9.3 Lymphoma (general)

9.3.1 Players and their Compared Pipeline

9.3.2 Where is the Real Competition?

9.3.3 How Successful are They in Their Targeting Strategy?

9.4 Non-Hodgkin’s Lymphoma

9.4.1 Players and their Compared Pipeline

9.4.2 Where is the Real Competition?

9.4.3 How Successful are They in Their Targeting Strategy?

9.5 T-cell Lymphoma

9.5.1 Players and their Compared Pipeline

9.5.2 Where is the Real Competition?

9.5.3 How Successful are They in Their Targeting Strategy?

10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator

10.1 Abbott

10.2 Abiogen

10.3 AEgera

10.4 Aeterna Zentaris

10.5 Affimed Therapeutics

10.6 Aida Pharmaceuticals

10.7 Alfa Wassermann

10.8 Alfacell

10.9 Allos Therapeutics

10.10 Amgen

10.11 Anadys Pharmaceuticals

10.12 Antigenics

10.13 Archer Biosciences

10.14 Ariad

10.15 Ascenta Therapeutics

10.16 Astellas

10.17 AstraZeneca

10.18 Attenuon

10.19 AVEO

10.20 Benitec

10.21 BioCryst Pharmaceuticals

10.22 Biogen Idec

10.23 Biolex

10.24 Boehringer Ingelheim

10.25 Borean Pharma

10.26 Bristol-Myers Squibb

10.27 BTG

10.28 Calistoga Pharmaceuticals

10.29 Cell Therapeutics

10.30 Cephalon

10.31 Cyclacel

10.32 Cylene Pharmaceuticals

10.33 Cytokinetics

10.34 Daiichi Sankyo

10.35 Dainippon Sumitomo Pharma

10.36 Dara Biosciences

10.37 Dynavax Technologies

10.38 Eisai

10.39 Eli Lilly

10.40 Enzon

10.41 EpiCept

10.42 Exelixis

10.43 Favrille

10.44 Gemin X Pharmaceuticals

10.45 Genentech

10.46 Genmab

10.47 GenPat77

10.48 Genta

10.49 Genzyme

10.50 GlaxoSmithKline

10.51 Gloucester Pharmaceuticals

10.52 Hayashibara

10.53 Hoffmann-La Roche

10.54 Human Genome Sciences

10.55 Hy BioPharma

10.56 ImClone Systems

10.57 Immunomedics

10.58 Inex

10.59 Innate Pharma

10.60 InNexus Biotechnology

10.61 Intracel

10.62 Italfarmaco

10.63 Johnson & Johnson

10.64 Kissei

10.65 Kyowa Hakko Kirin

10.66 Ligand

10.67 Lorus Therapeutics

10.68 MacroGenics

10.69 Meda

10.70 Medarex

10.71 MedImmune

10.72 MethylGene

10.73 Micromet

10.74 Nektar Therapeutics

10.75 National Institute of Health (USA)

10.76 Novartis

10.77 Oncothyreon

10.78 Pfizer

10.79 Pharmacyclics

10.80 PharmaMar

10.81 ProNAi Therapeutics

10.82 Reata Pharmaceuticals

10.83 Rigel

10.84 Sanofi-Aventis

10.85 Santaris Pharma

10.86 SBIO

10.87 Seattle Genetics

10.88 Shire

10.89 SuperGen

10.90 Takeda

10.91 Telik

10.92 Titan Pharmaceuticals

10.93 TopoTarget

10.94 Transgene

10.95 Trubion

10.96 Vaccinex

10.97 Vertex Pharmaceuticals

10.98 VGX Pharmaceuticals

10.99 Vion Pharmaceuticals

10.100 VioQuest

10.101 Wyeth

10.102 Xencor

10.103 Yakult Honsha

10.104 Zenyaku Kogyo

10.105 ZymoGenetics

10.106 Non-industrial Source

11 Disclaimer

12 Drug Index

13 Company Index

4.1 List of Figures

Figure 1: Overall Breakdown of the Included Lymphoma Therapeutic Pipeline by Sub-Indication and Stage of Development

Figure 2: Visualization of Target-Target Interactions Among Lymphoma Drug Targets

Figure 3: The Drug-Protein Interactome of Lymphoma Drugs -Clusters I

Figure 4: The Drug-Protein Interactome of Lymphoma Drugs - Clusters II

Figure 5: Head-to-Head Targeting Interactome of Lymphoma Drugs

Figure 6: Distribution of Compound Types among Lymphoma Drugs

Figure 7: Primary Sub-cellular Localization of Drug Targets

Figure 8: Breakdown of the B-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and

Investigators by Stage of Development

Figure 9: Breakdown of the B-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound

Strategy and Stage of Development

Figure 10: Breakdown of the Hodgkin’s Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles

and Investigators by Stage of Development

Figure 11: Breakdown of the Hodgkin’s Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound

Strategy and Stage of Development

Figure 12: Breakdown of the Lymphoma (general) Pipeline (I) - Displaying Number of Drugs, Target Profiles and

Investigators by Stage of Development

Figure 13: Breakdown of the Lymphoma (general) Pipeline (II) - Displaying the Number of Drugs by Compound

Strategy and Stage of Development

Figure 14: Breakdown of the Non-Hodgkin’s Lymphoma Pipeline (I) - Displaying Number of Drugs, Target

Profiles and Investigators by Stage of Development

Figure 15: Breakdown of the Non-Hodgkin’s Lymphoma Pipeline (II) - Displaying the Number of Drugs by

Compound Strategy and Stage of Development

Figure 16: Breakdown of the T-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and

Investigators by Stage of Development

Figure 17: Breakdown of the T-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound

Strategy and Stage of Development

4.2 List of Tables

Table 1: Competitive Pressure Force Among Lymphoma Drugs

Table 2: Overview of Drug Target Profile Themes

Table of Contents

BioSeeker Group AB © 2009 | www.bioseeker.com

Table 3: Drug Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the

Cancer Gene Census

Table 4: Identity of Lymphoma Drug Targets with Available Biological Structures

Table 5: Number of Target-Target Interactions among Lymphoma Drug Targets

Table 6: Drug-Protein Interactome Clusters

Table 7: Lymphoma Drug Targets with Available Protein Expression Profiles

Table 8: Pathway Summary

Table 9: Drug Targets without any Identified Assigned Pathways

Table 10: Pathway Profile According to BioCarta of Lymphoma Drug Targets

Table 11: Pathway Profile According to KEGG of Lymphoma Drug Targets

Table 12: Pathway Profile According to NetPath of Lymphoma Drug Targets

Table 13: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness

Table 14: Top Competitive Lymphoma Target Profiles

Table 15: Terminated Drug Target Profiles in Lymphoma

Table 16 New and Unique Lymphoma Targets in Pre-Registration to Marketed

Table 17: New and Unique Lymphoma Targets in Phase III Clinical Development

Table 18: New and Unique Lymphoma Targets in Phase II Clinical Development

Table 19: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs

Table 20 New and Unique Lymphoma Targets in Phase I Clinical Development

Table 21: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs

Table 22: New and Unique Lymphoma Targets in Preclinical Development

Table 23: The Progression, Maturity and Competitive Comparison of Lymphoma Drug Target Profiles in

Development

Table 24: Overview of Compound Strategy Competition in Lymphoma

Table 25:Overview of the Competitive Landscape of Small Molecular Drugs in Lymhpoma

Table 26: Head-to-head Target Competing Small Molecule Drugs for the Treatment of Lymphoma

Table 27: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in

Lymphoma

Table 28: The Progression, Maturity and Competitive Comparison of Small Molecule Lymphoma Drug Target

Profiles in Development

Table 29: The Progression, Maturity and Competitive Comparison of Peptide Based Lymphoma Drug Target

Profiles in Development

Table 30:Overview of the Competitive Landscape of Protein Based Drugs in Lymhpoma

Table 31: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in

Lymphoma

Table 32: The Progression, Maturity and Competitive Comparison of Protein Based Lymphoma Drug Target

Profiles in Development

4 Lymphoma Drug Development Strategies at Work - Define Your

Competition

18 Cancer Highlights No 1 Vol 9 2009| BioSeeker Group AB ©

Table 33:Overview of the Competitive Landscape of Antibody Drugs in Lymhpoma

Table 34: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lymphoma


Table 35: The Progression, Maturity and Competitive Comparison of AntibodyLymphoma Drug Target Profiles in

Development

Table 36:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lymhpoma

Table 37: The Progression, Maturity and Competitive Comparison of Nucleic Acid Lymphoma Drug Target

Profiles in Development

Table 38: Vectors in Gene Therapy

Table 39: The Progression, Maturity and Competitive Comparison of Gene Therapy Lymphoma Drug Target

Profiles in Development

Table 40: The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma

Table 41: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets

Table 42: Competitive Summary of Lymhpoma Drugs by Sub-Indication

Table 43: Players in the Field of B-cell Lymphoma Drug Development and their Compared Pipeline

Table 44: The Competition Through Close Mechanistic Approximation Between B-cell Lymphoma Drugs

Table 45: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in B-cell Lymphoma

Drug Development

Table 46: Players in the Field of Hodgkin’s Lymphoma Drug Development and their Compared Pipeline

Table 47: The Competition Through Close Mechanistic Approximation Between Hodgkin’s Lymphoma Drugs

Table 48: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Hodgkin’s

Lymphoma Drug Development

Table 49: Players in the Field of Lymphoma (general) Drug Development and their Compared Pipeline

Table 50: The Competition Through Close Mechanistic Approximation Between Lymphoma (general) Drugs .

Table 51: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lymphoma (general

)Drug Development

Table 52: A) Investigators with Multiple Non-Hodgkin’s Lymphoma Drugs in Development B) Investigators with

Ceased, Discontinued or Suspended Drugs

Table 53: Players in the Field of Non-Hodgkin’s Lymphoma Drug Development and their Compared Pipeline .

Table 54: The Competition Through Close Mechanistic Approximation Between Non-Hodgkin’s Lymphoma

Drugs

Table 55: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Hodgkin’s

Lymphoma Drug Development

Table 56: Players in the Field of T-cell Lymphoma Drug Development and their Compared Pipeline

Table 57: The Competition Through Close Mechanistic Approximation Between T-cell Lymphoma Drugs

Table 58: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in T-cell Lymphoma

Drug Development

Table of Contents

BioSeeker Group AB © 2009 | www.bioseeker.com

Table 59: Abbott's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 60: Abiogen's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 61: AEgera's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 62: Aeterna Zentaris’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 63: Affimed Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 64: Aida Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 65: Alfa Wassermann's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 66: Alfacell's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 67: Allos Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 68: Amgen's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 69: Anadys Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 70: Antigenics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 71: Archer Biosciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 72: Ariad's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 73: Ascenta Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 74: Astellas’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 75: AstraZeneca's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 76: Attenuon's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 77: AVEO's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 78: Benitec's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 79: BioCryst Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 80: Biogen Idec's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 81: Biolex's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 82: Boehringer Ingelheim's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 83: Borean Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 84: Bristol-Myers Squibb's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 85: BTG's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 86: Calistoga Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 87: Cell Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 88: Cephalon's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 89: Cyclacel's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 90: Cylene Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 91: Cytokinetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 92: Daiichi Sankyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 93: Dainippon Sumitomo Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out


Table 94: Dara Biosciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

20 Cancer Highlights No 1 Vol 9 2009| BioSeeker Group AB ©

Table 95: Dynavax Technologies’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 96: Eisai's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 97: Eli Lilly's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 98: Enzon's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 99: EpiCept's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 100: Exelixis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 101: Favrille's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 102: Gemin X Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 103: Genentech's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 104: Genmab's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 105: GenPat77's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 106: Genta's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 107: Genzyme's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 108: GlaxoSmithKline's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 109: Gloucester Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 110: Hayashibara's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 111: Hoffmann-La Roche's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 112: Human Genome Sciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 113: Hy BioPharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 114: ImClone Systems’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 115: Immunomedics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 116: Inex's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 117: Innate Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 118: InNexus Biotechnology's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 119: Intracel's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 120: Italfarmaco's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 121: Johnson & Johnson's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 122: Kissei's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 123: Kyowa Hakko Kirin's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 124: Ligand's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 125: Lorus Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 126: MacroGenics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 127: Meda's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 128: Medarex's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 129: MedImmune's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 130: MethylGene's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 131: Micromet's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 132: Nektar Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 133: National Institute of Health (USA)'s Included Lymphoma Pipeline Composition and Competitive Fall-

Out

Table 134: Novartis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 135: Oncothyreon's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 136: Pfizer's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 137: Pharmacyclics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 138: PharmaMar's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 139: ProNAi Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 140: Reata Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 141: Rigel's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 142: Sanofi-Aventis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 143: Santaris Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 144: SBIO's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 145: Seattle Genetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 146: Shire's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 147: SuperGen's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 148: Takeda's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 149: Telik's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 150: Titan Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 151: TopoTarget's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 152: Transgene's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 153: Trubion's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 154: Vaccinex's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 155: Vertex Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 156: VGX Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 157: Vion Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 158: VioQuest's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 159: Wyeth's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 160: Xencor's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 161: Yakult Honsha's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 162: Zenyaku Kogyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 163: ZymoGenetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out

Table 164: Non-industrial source's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Abstract

This report includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, T-cell lymphoma and Lymphoma (general)). The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products.

It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:
  • Providing you with competitive input to the R&D organization to guide development of early
    • product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting lymphoma sub-indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report will also be an important part of creating and implementing a market development plan for any lymphoma therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/15/2012 - 31